miR-206 integrates multiple components of differentiation pathways to control the transition from growth to differentiation in rhabdomyosarcoma cells by Kyle L MacQuarrie et al.
MacQuarrie et al. Skeletal Muscle 2012, 2:7
Skeletal Musclehttp://www.skeletalmusclejournal.com/content/2/1/7RESEARCH Open AccessmiR-206 integrates multiple components of
differentiation pathways to control the transition
from growth to differentiation in
rhabdomyosarcoma cells
Kyle L MacQuarrie1,2, Zizhen Yao1, Janet M Young1,3, Yi Cao1 and Stephen J Tapscott1,4*Abstract
Background: Similar to replicating myoblasts, many rhabdomyosarcoma cells express the myogenic determination
gene MyoD. In contrast to myoblasts, rhabdomyosarcoma cells do not make the transition from a regulative
growth phase to terminal differentiation. Previously we demonstrated that the forced expression of MyoD with its
E-protein dimerization partner was sufficient to induce differentiation and suppress multiple growth-promoting
genes, suggesting that the dimer was targeting a switch that regulated the transition from growth to
differentiation. Our data also suggested that a balance between various inhibitory transcription factors and MyoD
activity kept rhabdomyosarcomas trapped in a proliferative state.
Methods: Potential myogenic co-factors were tested for their ability to drive differentiation in rhabdomyosarcoma
cell culture models, and their relation to MyoD activity determined through molecular biological experiments.
Results: Modulation of the transcription factors RUNX1 and ZNF238 can induce differentiation in
rhabdomyosarcoma cells and their activity is integrated, at least in part, through the activation of miR-206, which
acts as a genetic switch to transition the cell from a proliferative growth phase to differentiation. The inhibitory
transcription factor MSC also plays a role in controlling miR-206, appearing to function by occluding a binding site
for MyoD in the miR-206 promoter.
Conclusions: These findings support a network model composed of coupled regulatory circuits with miR-206
functioning as a switch regulating the transition from one stable state (growth) to another (differentiation).
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Rhabdomyosarcoma (RMS) is a soft tissue sarcoma char-
acterized by expression of myogenic regulatory factors,
especially MyoD, and other skeletal muscle genes [1-3].
MyoD is capable of converting multiple cell types into
terminally differentiated skeletal muscle [4,5] and nor-
mally acts as a nodal point in differentiation to integrate
multiple signals to balance regulative growth and cell* Correspondence: stapscot@fhcrc.org
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distribution, and reproduction in any mediumdifferentiation [6]. However, in RMS the ability of MyoD
to induce differentiation is impaired [7].
Our recent study indicated that rhabdomyosarcomas
represent an arrested progress through a normal transi-
tional state that is regulated by the formation of hetero-
dimers between MyoD and the full-length E-proteins
[8]. MyoD binds DNA as a heterodimer with an E-pro-
tein (E2A, E2-2, or HEB) [9]. Normal myoblasts and
RMS express a transcriptionally less active splice form
of E2A as well as the bHLH (basic helix-loop-helix)
proteins ID and Musculin (MSC), both of which
compete with the full-length E-proteins for heterodi-
merization with MyoD. The demonstration that a
forced heterodimer of MyoD and a full-length E-proteinntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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induced differentiation in the RD and other rhabdo-
myosarcomas suggested that a central integrating
mechanism might regulate the switch from regulative
growth to differentiation [8].
If a central integrating mechanism does exist, then mul-
tiple pathways should regulate its activity and multiple fac-
tors should be able to induce differentiation in RMS. In this
manuscript we demonstrate that modulation of multiple
different myogenic factors can induce differentiation in
rhabdomyosarcoma cells and that their activity is inte-
grated, at least in part, through the activation of miR-206,
which acts as a genetic switch to transition the cell from a
proliferative growth phase to differentiation. These findings
suggest that multiple components of differentiation path-
ways that converge on miR-206 might be targeted for dif-
ferentiation therapies in at least some rhabdomyosarcomas.
Methods
Plasmid construction
Coding sequences of RUNX1 and ZNF238 were ampli-
fied by PCR from human myotube cDNA, and cloned
into pRRLSIN.cPPT.PGK/GFP.WPRE, pCLBabe, and
pCS2. The miR-206 lentivirus was purchased from Open
Biosystems. Lentiviral supernatant was produced by the
FHCRC core viral facility, and viruses from pCLBabe
plasmids packaged using BBS-mediated calcium precipi-
tation into Phoenix cells. MD~E2/5 was cloned into the
pCLBabe backbone. For the miR-206 promoter lucifer-
ase reporter, a piece of approximately 2.5 kb of DNA up-
stream of human miR-206 was amplified using primers
located in (Additional file 1: Table S1).
Cell culture, transient transfections, and luciferase assays
RD cells were obtained from ATCC (American Type Cul-
ture Collection) in approximately 1990, and all analyses
have been performed on cells that originated from low pas-
sage number frozen aliquots. RhJT cells were obtained from
PJ Houghton in 1990 and, as with RD cells, all experiments
have used cells from original low passage number frozen
cells. RD and RhJT cells were maintained in DMEM with
10% bovine calf serum and 1% Pen-Strep (Gibco, Grand Is-
land, USA). Low-serum differentiation media consisted of
DMEM with 1% horse serum, 1% Pen-Strep and 10 μg/mL
insulin and transferrin. Transient transfections for lucifer-
ase assays were performed using Superfect according to
manufacturer’s directions with a total of 3 ug of plasmid
DNA in each well (Qiagen, Valencia, USA). Luciferase
assays used the Dual-Luciferase Assay kit (Promega, Madi-
son, USA) according to manufacturer’s directions. All
results were corrected to co-transfected Renilla-pCS2 and
are reported as the mean±SEM of at least three independ-
ent experiments, with significance calculated using a t-test,
and each experiment having three biological replicates ofall conditions. Transient transfections of pre-microRNA
constructs were performed using 25 μM of pre-miR con-
structs (Ambion, Grand Island, USA) and siPORT NeoFX
(Ambion) according to the manufacturer’s directions.qPCR and RT-PCR
All qPCR was performed using SybrGreen from Bio-Rad
on an Applied Biosystems 7900HT. Relative expression
levels were calculated using cDNA dilution standard
curves or delta-delta Ct calculations. All values are
reported as the mean±SEM of at least three independent
biological experiments and significance tested with t-tests.
All RT-PCRs were performed simultaneously with minus
reverse transcriptase controls to check the absence of sig-
nal. Primers used for amplification are listed in (Additional
file 1: Table S1).microRNA microarrays
RNA was isolated using acid-phenol purification from
two biologically independent sets of RD cells transduced
with either MD~E or empty vector pCLBabe retro-
viruses and differentiated for 24 h after puromycin selec-
tion. miRNAs were labeled using Exiqon’s miRCURY
labeling kit, and then competitively hybridized to in-
house spotted miRNA arrays (FHCRC core facility). Cut-
offs for significant changes were a FDR <0.05 and a
fold-change >2. Data are available under GEO accession
number GSE35921.microRNA northerns
microRNA northern blots were performed as described
previously [10]. Probe sequences used are listed in (Add-
itional file 1: Table S1).Expression microarrays
RNA was isolated using the RNeasy mini kit (Qiagen)
from RD cells infected with either RUNX1-, ZNF238-,
miR-206-, or GFP-expressing lentiviruses and allowed to
differentiate for 72 h. Each condition was performed
with three independent biological replicates. RNA was
hybridized to Illumina Human HT-12 v4 BeadChips.
Analysis was performed in R/Bioconductor using the
lumi and limma packages with annotations found in the
lumiHumanAll.db package. P values were adjusted to ac-
count for multiple testing using Benjamini and Hochberg’s
method, and cutoffs for significant changes were a FDR
<0.05 and a fold-change >2. GO category enrichment
tests were performed using the conditional algorithm of
the GOstats package and a gene ‘universe’ of any gene
with a GO annotation that was called as ‘present’ in at
least one of the 12 array datasets. Data are available
under GEO accession number GSE35921.
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ChIPs were performed as has been described previously
[11]. Antibodies used were as follows: RUNX1 (Abcam,
ab23980), MyoD [12], MSC (Santa Cruz, sc-9556X),
Acetylated Histone H4 (Upstate 06-866). Primers used
for amplification are listed in (Additional file 1: Table S1).
EdU and BrdU labeling, western blots, and cell stains
After 24 h in low-serum differentiation media, cells were
shifted to differentiation media supplemented with EdU
at a final concentration of 50 μM (Invitrogen) and incu-
bated for a further 24 h. Cells were then fixed and
stained according to the manufacturer’s protocols using
the Click-iT kit, and total nuclei and EdU positive nuclei
counted by hand.
RD cells were labeled with BrdU at a final concentra-
tion of 30 μg/mL in differentiation media for 24 h. Cells
were treated with hydrochloric acid before incubation
with anti-BrdU antibody (Invitrogen A21300), and fluor-
escent secondary antibody (Jackson Immunoresearch).
Nuclei were detected with DAPI, and cells counted by
hand.
Western blots were performed on whole cell
lysates collected in Laemelli buffer containing 10%
beta-mercaptoethanol. All blots were blocked in 3% milk
(w/v) in 0.5% Tween-20-containing PBS before incubation
with primary antibody (MHC: MF-20, MyoD: 5.8A,
RUNX1: Abcam, ab23980), a HRP-conjugated secondary
antibody (Jackson, West Grove, USA), and chemilumines-
cent detection (Amersham, Pittsburgh, USA).
Cells were fixed with 2% paraformaldehyde for
6 min at room temperature before permeabilization
with Triton X-100. Myosin heavy chain was detected
with the MF-20 antibody, and nuclei detected with
DAPI.
Electrophoretic mobility shift assays
Electrophoretic mobility shift assays were performed as
described previously [13]. Probe sequences are listed in
(Additional file 1: Table S1).
Results
RUNX1 and ZNF238 differentiate rhabdomyosarcoma cells
RUNX1 is a runt-related transcription factor with a well-
characterized hematopoietic role [14] that is expressed
in muscle cells [15], functions in denervated muscle
[16], and is regulated by the MyoD network [8,17], but
has an uncharacterized role in developing muscle.
ZNF238 (aka RP58) is induced by MyoD and directly
down-regulates the inhibitory Id factors [18]. MyoD
ChIP-seq (chromatin immunoprecipitation coupled to
high-throughput sequencing) found an association be-
tween the RUNX1 and ZNF238 binding motifs and
MyoD bound sites in muscle cells [11] and qPCRconfirmed that both RUNX1 and ZNF238 increased with
differentiation induced in the RD RMS line by the forced
MD~E dimer and that myotubes formed from MyoD-
induced myogenesis in normal fibroblasts had higher ex-
pression levels of both factors compared to RD cells
(Figure 1A and 1B). Therefore, we hypothesized that
RUNX1 and/or ZNF238 might cooperate with MyoD to
drive muscle gene expression and tested each factor for
its ability to induce differentiation in RD cells.
Lentiviral-mediated expression of each factor in RD
cells (Additional file 2: Figure S1) induced muscle differ-
entiation, as measured by morphology and expression of
myosin heavy chain (MHC) (Figure 1C), muscle-specific
creatine kinase (CKM) (Figure 1D), and withdrawal from
the cell cycle based on EdU incorporation (Figure 1E).
As in normal myogenesis, expression of ZNF238
decreased both ID2 and ID3 (Figure 1F). This differenti-
ation is not restricted to the embryonal RMS RD cell
line; the RhJT alveolar line expressing RUNX1 showed
similar results (Additional file 3: Figure S2).
miR-206 expression correlates with factor-induced
differentiation in RMS cells
We previously demonstrated that the expression of the
MD~E dimer in RD cells down-regulated multiple myo-
genic inhibitors [8], consistent with induction of a
microRNA. MicroRNA microarrays from MD~E trans-
duced RD cells identified several microRNAs that chan-
ged expression and miR-206, a microRNA that has been
shown to induce myogenic differentiation in normal
cells and RMS [19,20], was the most consistently
increased (Additional file 4: Table S2) and was confirmed
by miRNA Northern blotting (Figure 2A, upper panel),
as was miR-133b, a miRNA from the same primary tran-
script (Figure 2A, second panel). RT-PCR for the pre-
sumptive primary transcript also showed a substantial
increase (Figure 2B). Northern blotting confirmed that
the forced dimer decreased miR-199a* expression, as sug-
gested by the array results (Additional file 5: Figure S3A),
and that miR-29b, previously implicated in RMS differ-
entiation, was expressed at low levels and did not
change in response to MD~E expression (Additional
file 5: Figure S3B) [21]. Furthermore, RD cells differen-
tiated through RUNX1 and ZNF238 expression showed
an increase in mature miR-206 in both cases (Figure 2C),
along with an increase in primary transcript (data not
shown). miR-206 levels in the myogenic C2C12 cell line
showed that miR-206 expression in proliferative and dif-
ferentiated RMS resembled the changes as C2C12 cells
shift from beginning myogenesis (90% confluency) to
myotubes (DM) (Figure 2D).
In agreement with previous reports demonstrating that
miR-206 alone is sufficient to differentiate RMS cells
[20,22,23], transient transfection of pre-miR-206 constructs
Figure 1 Expression of RUNX1 or ZNF238 leads to terminal differentiation of RMS cells. (A) qPCR for RUNX1 was performed in RD cells
either infected with a control virus, or the forced MyoD~ E dimer (MD~ E) as well as control (0 h) human fibroblasts and fibroblasts differentiated
into myotubes (96 h). (B) RT-PCR for the two isoforms of ZNF238 in RD cells and fibroblasts as in 1A. (C) Myosin heavy chain (MHC) immunostains
in RD cells either not infected (no infection), infected with a control GFP-expressing lentivirus (GFP control) or RUNX1 or ZNF238 expressing
lentivirus. All cells were infected at approximately equivalent MOIs, and cells were allowed to differentiate for 72 h in low-serum media before
staining. GFP was detected directly, without the use of an antibody. (D) qPCR for muscle-specific creatine kinase (CKM) in RD cells infected with
either ZNF238 or RUNX1 viruses compared to cells with control retroviruses. (E) After 24 h of differentiation, RD cells were pulsed for a further
24 h with EdU-containing differentiation media, before fixation and quantification of the percentage of EdU-positive cells. (F) qPCR for ID2 and
ID3 in control and ZNF238-expressing RD cells. All qPCR data are normalized to TIMM17b expression, and the level in control cells is set to 1. All
bar graphs represent the mean± SEM of at least three independent experiments. *: P< 0.05; **: P< 0.01; ***: P< 0.001; ****: P< 1 × 10-4
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an increase in CKM expression (Figure 2F), and evidence
that cells undergoing morphological change withdrew
from the cell cycle (Figure 2G, H), with similar results in
the alveolar RhJT cells (Additional file 6: Figure S4A anddata not shown). As would be expected from prior reports
of its effect on myogenic cells [24], introduction of miR-
133b did not lead to RMS differentiation as judged by ei-
ther morphology or gene expression (Additional file 6:
Figure S4B, C).
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RUNX1 binding site exists near the MyoD binding site.
RUNX1 alone showed minor activation of a miR-206
luciferase reporter, while RUNX1 combined with MyoD
showed synergistic activation (Figure 2I, black bars),
which was dependent on the integrity of the RUNX1
binding site (Figure 2I, grey bars). ChIP experiments in
RD cells confirmed that RUNX1 binds the miR-206 pro-
moter (Figure 2J). Therefore, RUNX1 cooperates withFigure 2 (See legend on next page.)MyoD to enhance the expression of miR-206. ZNF238
did not activate the miR-206 reporter (data not shown),
suggesting that the reporter does not have the elements
or context for ZNF238 regulation.
RUNX1 also induced the expression of ZNF238 in RD
cells and ChIP identified RUNX1 binding close to the
TSS of ZNF238, suggesting it functions directly to acti-
vate ZNF238 (Figure 3A and 3B). Consistent with
this model, ID2 and ID3 expression were decreased
(See figure on previous page.)
Figure 2 MyoD~E, RUNX1, and ZNF238 increase miR-206. (A) microRNA northern blots to detect the mature form of the indicated
microRNAs in RD cells infected with either empty (control) retrovirus, or retrovirus expressing MyoD~ E (MD~ E). (B) RT-PCR using primers located
in the pre- and pri-miR-206 sequence to detect the primary miR-206 transcript. TIMM17b is the internal control. (C) microRNA northerns as in 2A,
in RD cells expressing a transcription factor as indicated. (D) microRNA northerns in C2C12 cells at various stages of differentiation ranging from
undifferentiated myoblasts (50% GM), through beginning differentiation (90% GM) to myotubes (DM). (E) Immunostains for MHC in RD cells
transiently transfected with either a pre-miR-206 RNA construct, or a negative control construct. Nuclei were stained with DAPI. (F) qPCR for CKM
in RD cells treated as in E. (G) RD cells treated as in E were pulsed with BrdU for 24 h and then stained and counted to determine the extent of
co-localization of MHC+myotubes and BrdU+ nuclei. (H) RD cells transiently transfected as in E were pulsed for 24 h with BrdU-containing
differentiation media before fixation and quantification of the percentage of BrdU positive cells. The percent reduction of BrdU+ nuclei almost
exactly equals the percent of cells found to be MHC+ (not shown). (I) Luciferase activity in RD cells using a miR-206 promoter driven reporter and
transiently transfected factors as indicated. ‘206 RUNX mutant’ indicates that the reporter has had a putative RUNX1 binding site mutated to
prevent RUNX1 binding. Control indicates transfection with an empty plasmid. All luciferase assays were normalized to the results from a co-
transfected renilla plasmid. (J) RUNX1 ChIP assays, both with normal PCR and qPCR results, at the miR-206 promoter and a control locus before
(Control) and after (RUNX1) infection of the cells with empty or RUNX1-expressing retrovirus. All PCRs in the imaged gel (upper) were performed
for the same number of cycles. qPCR results (lower) represent the mean± SEM of two independent ChIP experiments. Relative enrichment is
calculated as the ratio of the % of input amplified with antibody to the % of input amplified with no antibody. All other graphs in this figure
represent the mean± SEM of at least three independent experiments. * : P< 0.05; ** : P< 0.01; *** : P< 0.001.
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trast, ZNF238 did not upregulate RUNX1 expression,
but we confirmed the prior report [18] that MyoD
activates ZNF238 (Additional file 7: Figure S5).Figure 3 ZNF238 is a downstream target of MyoD and RUNX1. (A) qP
the converse factor. (B) RUNX1 ChIP results at the intron of ZNF238 and a c
with empty or RUNX1-expressing retrovirus. (C) qPCR for ID genes in contro
performed for the same number of cycles. The graph in 3B represents qPC
Relative enrichment is calculated as the ratio of the % of input amplified w
3A and 3C are represented as the mean± SEM of at least three independeTogether, this shows that MyoD functions in nested
feed-forward circuits with RUNX1 and ZNF238 to
activate miR-206 expression and induce differenti-
ation in the RD cells.CR for RUNX1 and ZNF238 in RD cells transduced with virus expressing
ontrol locus before (Control) and after (RUNX1) infection of the cells
l and RUNX1-expressing RD cells. PCRs in the imaged gel in 3B were
R data showing the mean± SEM of two independent experiments.
ith antibody to the % of input amplified with no antibody. qPCRs in
nt experiments. *: P< 0.05; **: P< 0.01.
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differentiation program
Gene expression arrays were performed on RD cells
transduced individually with RUNX1-, ZNF238-, and
miR-206 expressing viruses. GO analysis ranked by
P values identified multiple muscle-related categories
induced by each factor, with four of the ten most signifi-
cant categories shared between all factors (Additional
file 8: Table S3). In agreement with our deduced epistatic
relationship, the number of genes significantly regulated
(fold change> 2, FDR <0.05) by each factor became se-
quentially reduced from RUNX1 (734) to ZNF238 (616)
to miR-206 (355) and showed substantial overlap
(Figure 4A) and correlation (Figure 4B). Loosening the
fold-change threshold showed that nearly all genes regu-
lated by miR-206 similarly changed expression in re-
sponse to RUNX1 and/or ZNF238 (Figure 4C, top).
Similarly, a large portion of the ZNF238 genes were also
regulated by RUNX1 (Figure 4C, bottom).
RUNX1, ZNF238, and miR-206 affected the expression
of a variety of transcription factors and signaling path-
ways involved in myogenesis (Additional file 9: Table S4),
and a subset of the changes were confirmed by RT-PCR
(Figure 4D). The MRF myogenin, a MyoD target [26],
increased in response to all three of the factors. MEF2C
and MEF2D, cooperative factors for MyoD activity [17],
were up-regulated. Down-regulation of positive regula-
tors of the cell cycle (MYCN, RCOR2, E2F2) and various
members of the HES/HEY family (HEY1, HES6, HEYL,
HES1) was observed as well. It has previously been
demonstrated that interference with HES1 contributes
to RMS proliferation [27], and the HES/HEY family is
known to be Notch responsive [28], a signaling pathway
with myogenic inhibitory effects [29-31]. Among miR-
206’s most strongly down-regulated targets were two
members of the Notch signaling pathway, DLL3 and
NOTCH3.The miR-206 promoter integrates multiple inputs to
switch from inhibition by MSC to activation by MyoD
We have previously shown that MyoD binds and acti-
vates the expression of the miR-206 gene in normal
myogenesis [25], whereas our current data indicate that
the miR-206 promoter integrates multiple inputs to
modulate its activation by MyoD. Somewhat to our sur-
prise, ChIP in RD cells showed that MyoD was bound to
the miR-206 promoter in undifferentiated RD cells that
expressed only low levels of miR-206 (Additional file 10:
Figure S6A) and regional enrichment for acetylated H4
histones indicated active regional histone acetyltransfer-
ase activity (Additional file 10: Figure S6B). Therefore, a
factor, or factors, was preventing efficient transcriptional
activation by the bound MyoD.We have previously shown that the inhibitory bHLH
factor Musculin (MSC) inhibits MyoD activity in RD
cells and other RMS [8]. Furthermore, since miR-206
has been shown to inhibit MSC expression [19], we
hypothesized that the opposing activities of MyoD and
MSC might constitute an on-off switch at the miR-206
promoter. ChIP showed that MSC was bound to the same
region as MyoD in undifferentiated RD cells (Figure 5A),
and MSC occupancy diminished in RD cells that under-
went RUNX1- (Figure 5B) or MD~E-mediated differenti-
ation (Additional file 11: Figure S7). High-throughput
sequencing of the MyoD and MSC ChIP material
(ChIP-seq) from undifferentiated RD cells with analysis
restricted to sequences mapping to the miR-206 promoter
revealed distinct MyoD and MSC peaks over two adjacent
E-boxes (Figure 5C), indicating a MyoD bound E-box adja-
cent to a MSC bound E-box.
Electrophoretic mobility shift assaysdemonstrated that
the E-box associated with the MyoD peakhad a higher
affinity for MyoD compared to the E-box underthe MSC
peak, but that both E-boxes can be bound by either-
MyoD or MSC in vitro (Additional file 12: Figure S8).
Whenthe E-protein is in excess, gel shift assays show that
MyoD:Eheterodimers can compete with MSC:E heterodi-
mers to bindthe E-box under the MyoD ChIP-seq peak
(Figure 5D, leftpanel, lane 1) and that decreasing the
amount of MSC shiftsthe binding progressively toward
MyoD:E protein heterodimers(lanes 2–5). Even with a rela-
tive excess of E-protein,MSC:E heterodimers outcompete
MyoD:E heterodimers onthe E-box under the MSC
ChIP-seq peak andMyoD:E bindingto this site occurred
only when MSC levels were decreased (Figure 5D, right
panel, lanes 1–5). Therefore the relative affinitiesof MSC:E
and MyoD:E heterodimers for the two E-boxesin the
miR-206 regulatory regions likely account for theob-
served endogenous binding (Figure 5C) and suggest that
decreasinglevels of MSC would result in occupancy of both
E-boxes by MyoD.
Co-transfection experiments showed that MyoD:E12
heterodimers robustly activated the miR-206 reporter
containing both E-boxes and this was prevented by
MSC (Figure 5E, black bars). MSC also repressed ac-
tivation by the MD~E dimer, suggesting the effect of
MSC is due to DNA binding, not interference with
the formation of MyoD:E dimers (Additional file 13:
Figure S9). Mutation of the MSC binding site made
the reporter insensitive to activation by MyoD and
E12 (Figure 5E, grey bars). This suggests that MSC is
repressing miR-206 by physically occluding an E-box
that MyoD needs to occupy for full activation. The
MyoD and MSC ChIP-seq data also supports this
conclusion. Compared to the MyoD peak in RD cells,
there is a broadening of the MyoD peak in myotubes
that appears to widen to include E-boxes located
Figure 4 RUNX1, ZNF238, and miR-206 function through common mechanisms. (A) 3-way Venn diagram representing the overlap between
significantly regulated (fold-change >2, FDR <0.05, overlap considers only changes in same direction) gene targets in RD cells differentiated
either through RUNX1, ZNF238, or miR-206 expression relative to GFP-infected controls. The table indicates the breakdown of upregulated versus
down-regulated genes for each portion of the Venn diagram. (B) Scatter plots showing pairwise comparisons of gene expression. All values are
plotted as the log2 of the fold-change relative to GFP-infected controls, as indicated along the x- and y-axes. Correlation is listed for each
comparison in the matrix. (C) (upper panel) Bar graph demonstrating that the majority of the 95 genes listed as being ‘uniquely’ regulated by
miR-206 in 4A are also regulated by RUNX1 and/or ZNF238, but at lower levels of expression change. FDR was kept constant (<0.05) in this
analysis, and to be included as a ‘shared’ target, the change had to occur in the same direction (either up- or down-regulated) in RUNX1 and/or
ZNF238 as in miR-206. (bottom panel) Analysis as in the top panel for genes in the ZNF238 unique and ZNF238:miR-206 intersection groups
relative to RUNX1 changes. (D) RT-PCR for select gene targets from Additional file 9: Table S4. TIMM17b serves as the internal control.
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script (Figure 5C, bottom panel), suggesting that in
differentiated muscle, MyoD occupies additional positions.
Consistent with a model in which miR-206 activity
requires multiple E-boxes to be bound by MyoD for full
activation, mutation of the MyoD-binding E-box also
resulted in a dramatic reduction in the ability of the re-
porter to be activated by MyoD and E12 (Additional file
14: Figure S10).
An alternative splice form of E2A modulates MyoD
activation of miR-206
We previously described a developmentally regulated
splice form of E2A that removes a portion of the firstactivation domain by splicing exon 2 directly to exon 5
that we called E2A-2/5. To determine whether the E2A-
2/5 splice form contributed to the bHLH balance at the
miR-206 promoter, we tested the response of RD cells to
expression of a forced protein dimer consisting of MyoD
and the E12-2/5 splice form of E12 (MD~E2/5). MD~
E2/5 expressing cells formed substantially fewer myo-
tubes (Additional file 15: Figure S11A) while expressing
roughly equivalent amounts of dimer (Additional file 15:
Figure S11B) compared to cells expressing the full-length
MD~E dimer. MD~E expressing cells expressed sub-
stantially more CKM (Figure 5F), RUNX1 (Figure 5G),
and miR-206 (Figure 5H) than MD~E2/5 cells. However,
in all cases, MD~E2/5 expressing cells still expressed
Figure 5 (See legend on next page.)
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Figure 5 MSC interferes with the ability of MyoD to positively regulate the microRNA miR-206 by blockading a necessary MyoD-binding
site. (A) Site-specific ChIP for MSC in the miR-206 promoter and at a control locus. (B) MSC ChIP as in (A) in RD cells infected either with an
empty retrovirus (Control), or RD cells differentiated through expression of RUNX1 (RUNX1). (C) Screenshot from the human UCSC Genome
Browser of the region that corresponds to the miR-206 promoter. Mapped reads from ChIP-seq for MyoD in RD and HFF cells are indicated, with
the number on the left-hand y-axis indicating the number of reads mapped at the peak of occupancy. The location of E-boxes are indicated at
the bottom of the panel by the black rectangles. Vertical lines are drawn through the apparent highest points of occupancy for MyoD (red) and
MSC (green) in RD cells. (D) Electrophoretic mobility shift assays using in vitro transcribed and translated proteins as indicated and probes that
correspond to either the E-box located at the peak of MyoD binding as indicated by the red mark in 5C, or the E-box located at the peak of MSC
binding, indicated by the green mark. The position of MyoD:E and MSC:E heterodimers are indicated by the arrows. The lane marked 2x E12
indicates protein mixtures that included double the amount of E12 compared to other lanes, and the triangles indicate decreasing amounts of
either MSC or MyoD in the mixtures as other proteins were maintained at constant levels and total protein amounts were balanced with
translation of empty CS2. (E) Luciferase assays in RD cells with constructs as indicated below the figure using either the miR-206 promoter
luciferase reporter (206) or one in which the E-box that the peak of MSC occupancy is located over has been mutated (206 MSC-binding Ebox
mutant). Control indicates transfection with an empty plasmid. All luciferase assays were normalized to the results from a co-transfected renilla
plasmid. (F) qPCR for CKM from RD cells transduced with either an empty virus (control), or one expressing either the MD~ E or MD~ E2/5 forced
dimer. Cells were differentiated for 24 h before collection of RNA for use in qPCR. (G) qPCR for RUNX1 from the RD cells assayed in E. (H) qPCR for
pri-miR-206 from the RD cells assayed in E and F. For all ChIPs, relative enrichment is calculated as the ratio of the % of input amplified with
antibody to the % of input amplified with no antibody. The control locus is located at hemoglobin beta, a silent gene in myogenic cells.
Corrected relative enrichment (5B) is the ratio of enrichment at miR-206 to enrichment at the control locus. All graphs represent the mean± SEM
of at least three independent experiments. All qPCR of gene expression was corrected to TIMM17b and control cells set to 1.
* : P <0.05; ** : P< 0.01; *** : P< 0.001; † : P= 0.058.
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that, while the specific E-protein partner is important for
full activation of miR-206, the inhibitory effect of MSC is
crucial.
Discussion
We have previously proposed that RMS represent an
arrested phase of normal development at the transition
point between regulative growth and terminal differenti-
ation, a transition regulated in part through the balance
of repressive and activating bHLH protein dimers [8].
We showed that increasing the abundance of MyoD:E-
protein heterodimers tipped the balance to differentiation
and proposed that this heterodimer might target an un-
known central integrating function since multiple myo-
genic repressors were down-regulated. One prediction of
this earlier model was that modulating the abundance of
any of the factors that impinge on the integrating func-
tion might be sufficient to induce differentiation in RMS.
Our present study supports and extends this model by
demonstrating that miR-206 integrates the activity of
multiple proliferative and myogenic factors and acts as a
switch that transitions the RMS from growth to
differentiation.
To test whether different myogenic co-factors can in-
duce differentiation in RMS, we chose one transcrip-
tional activator and one repressor, RUNX1 and ZNF238,
respectively. RUNX1 enhances MyoD activation at a var-
iety of MyoD targets, including ZNF238 and possibly
MYOG and the MEF genes. In contrast, ZNF238 down-
regulates multiple members of the inhibitory HES and
HEY protein family and factors that drive proliferation.
Our data on ZNF238 regulation, motif analysis, and gene
targets in this and previous work [11] suggest that theinduction of this inhibitory factor serves two purposes:
(1) to down-regulate genes that inhibit myogenesis; and
(2) to interfere with MyoD binding at genes it might
regulate in myoblasts. Despite differences in their direct
targets, RUNX1 and ZNF238 both increase miR-206
transcription and lead to a terminally differentiated state.
For RUNX1 we demonstrated a direct binding of the
miR-206 promoter, whereas the mechanism for ZNF238
remains speculative, possibly through its suppression of
ID gene expression, which would increase the propor-
tion of productive MyoD:E-protein heterodimers. While
in vitro in nature, our data on the relative ability of
MyoD:E and MSC:E to shift the regulatory E-box
sequences that control miR-206 expression (Figure 5D
and Additional file 12: Figure S8) suggest that even rela-
tively small changes in the availability of E-protein part-
ners could make a dramatic difference in the expression
of miR-206.
MSC, a bHLH that inhibits myogenesis [32], sup-
presses the activation of miR-206 by binding an E-box
required for induction by MyoD. A requirement for
more than one MyoD-bound E-box to drive full target
activation has been described before [33-37], and it is
currently unclear whether MSC is simply preventing
MyoD binding or recruiting repressive factors to the
locus. The fact that the miR-206 locus has acetylated H4
even when not robustly expressed suggests that MSC
may have a simple obstructionist role at this locus. Fu-
ture work will be necessary to determine the relative
roles of MSC and MyoD at miR-206 and other myogenic
targets.
Data reported in this manuscript, when combined with
previous data from us and others [8,11,18,19] suggests a
specific model for the regulation of miR-206 that involves
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loops to create a molecular switch for regulating the tran-
sition from growth to differentiation in myogenic cells
(Figure 6). In replicating myoblasts, a MyoD:E-protein het-
erodimer binds an E-box site in the regulatory regions of
ID2 and ID3 [11] creating the potential for an oscillating
circuit: any increase in MyoD activity would increase ID
expression, which would dampen MyoD activity by de-
creasing the availability of the E-protein dimer partner.
However, if MyoD:E-protein heterodimers pass a threshold
of activity sufficient to initiate a feed-forward circuit acti-
vating RUNX1 and ZNF238, then ZNF238 shuts off ID
production by occluding the MyoD binding sites and
thereby relieving the negative-feedback regulation of
MyoD. The increased MyoD and RUNX1 activity can then
more effectively compete with MSC on the miR-206 regu-
latory regions and the increased miR-206 levels feed back
to inhibit MSC, and likely other growth promoting factors
[8,19,20,24,38], thereby locking the cell into a committed
differentiation program. Therefore, miR-206 integrates theFigure 6 miR-206 integrates the output of oscillating circuits and acts
The experimental data support a network model composed of coupled osc
from one stable state to another. In myoblasts, MyoD, E-proteins, and ID pr
bind an E-box in the regulatory regions of the ID2 and ID3 genes and driv
the E-protein, limiting the production of active MyoD:E-protein heterodime
ID production; and (4) the decreased ID permits an increase in active MyoD
oscillating circuit is composed of MyoD, E-proteins, MSC, and miR-206: (1) M
at the E-box in the miR-206 regulatory region, which oscillates between M
protein prevent full activation by MyoD; and (3) low levels of miR-206 prev
response to the concentration of active MyoD:E-protein heterodimers. The
concentration and/or activity of the MyoD:E-proteins become sufficient to
that blocks the expression of the ID genes and permits the accumulation o
heterodimers together with RUNX produces higher miR-206 expression, an
differentiation.output of oscillating circuits and acts as a genetic switch to
transition the cell from a proliferative growth phase to
differentiation.
Hematological malignancies are often categorized based
on an arrested transition between stages of cellular differen-
tiation. Our work suggests that the same might apply to
RMS and possibly other solid tumors. bHLH factors control
cell fate and differentiation in multiple cell types and a bal-
ance among bHLH dimer partners and other co-factors
might establish similar ‘tipping points’ at critical genes that
regulate the transition from regulative growth to differenti-
ation. Our emerging model of multiple pathways (some
functioning as oscillating circuits) integrated by switch-
points for differentiation has significant implications for
drug therapies to induce differentiation. Different cell types
may not exhibit identical convergence of pathways. There-
fore, combining multiple drugs that each has a small
effect on different components might induce differen-
tiation in the target cells while exhibiting low toxicity
and few off-target effects.as a genetic switch to transition from growth to differentiation.
illators with miR-206 functioning as a switch regulating the transition
oteins compose the first oscillating circuit: (1) MyoD:E heterodimers
e ID transcription; (2) the ID protein competitively forms dimers with
rs; (3) the decline in active MyoD:E-heterodimers results in decreased
:E-protein heterodimers and more ID production. The second
yoD:E-protein and MSC:E-protein heterodimers compete for binding
yoD-activated and MSC-repressed states; (2) limiting amounts of E-
ent full suppression by MSC. These circuits are coupled by their shared
oscillating circuits bifurcate to a new determined state when the
activate the expression of RUNX1 and ZNF238 in a feed-forward circuit
f active MyoD:E-protein complexes. The increase of MyoD:E-protein
d the increased miR-206 suppresses MSC and other inhibitors of
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Our results in a rhabdomyosarcoma cell line provide evi-
dence for feed-forward and feed-back regulatory circuits
in myogenic cells that regulate miR-206 expression as a
genetic switch to transition a muscle cell from growth to
differentiation. One circuit is composed of MyoD,
RUNX1, ZNF238, and ID2/3 and might function, at least
in part, to regulate the availability of E-proteins to form
heterodimers with MyoD; whereas the second circuit
composed of MyoD, RUNX1, and MSC regulates the ex-
pression of miR-206. These have characteristics of
coupled oscillatory circuits that can dampen the activity of
MyoD during expansionary growth, or, under differenti-
ation promoting conditions, can be switched off and
thereby enhance MyoD activity and drive differentiation.
Modulating the abundance of multiple different compo-
nents of these coupled circuits can drive differentiation,
suggesting that multiple targets within these circuits
might be candidates for targeting differentiation-inducing
therapeutics.Additional files
Additional file 1: Table S1. Primer and oligonucleotide sequences.
Additional file 2: Figure S1. RD cells infected with ZNF238 and RUNX1
viruses increase expression of the appropriate factor. (A) RT-PCR for
ZNF238 in RD cells infected with either a control virus or the ZNF238-
containing virus. TIMM17b is used as a loading control. (B) Western blot
using whole cell lysates for RUNX1 in control and RUNX1 virus infected
RD cells. The blot was then stripped and reprobed for alpha-tubulin as a
loading control. Bands were confirmed to be of the correct size through
a protein size ladder (not shown).
Additional file 3: Figure S2. RUNX1 differentiates alveolar subtype RMS
cells. (A) Western blots on whole cell lysates from RhJT cells infected with
either a RUNX1-expressing or control virus. MHC is myosin heavy chain, a
marker of myogenesis, and alpha-tubulin is the loading control. Blots
were serially stripped and reprobed, and bands confirmed to be of the
correct size. (B) RT-PCR for CKM (muscle specific creatine kinase) on cells
treated as in A. TIMM17b is the internal control.
Additional file 4: Table S2. miRNA changes in response to MD~E
expression in RD cells.
Additional file 5: Figure S3. Differential effects on miRNA expression
by the forced MD~E dimer. (A) miRNA northern blot for miR-199a* (also
known as miR-199a-5p) from RD cells either transduced with a control or
MD~E virus. (B) miRNA northern blot for miR-29b as in panel A.
Additional file 6: Figure S4. miR-206 affects alveolar subtype RMS cells
and miR-133b does not share its effects. (A) Immunostains for MHC in
RhJT cells transfected with either a pre-miR-206 or control construct.
DAPI stains all nuclei. (B) Stains as in A after transfection of RD cells with
pre-miR-133b or a control construct. (C) qPCR for CKM in RD cells treated
as in B. qPCR data was normalized to TIMM17b and control set to 1, with
bars representing the mean ± SEM of three independent experiments. *:
P<0.05.
Additional file 7: Figure S5. MyoD activity increases ZNF238 expression
during myogenic conversion. 10T1/2 fibroblast cells expressing an
estradiol-inducible version of MyoD were induced to undergo
myogenesis by addition of beta-estradiol to the culture medium. RNA
was taken at the indicated times under indicated conditions and qPCR
performed to quantitate the relative levels of ZNF238. All bars indicate
the mean ± SEM of at least three independent experiments. Time 0 was
set to 1, and TIMM17b served as the internal control. *: P<0.05.Additional file 8: Table S3. Top GO categories of genes regulated by
RUNX1, ZNF238, and miR-206.
Additional file 9: Table S4. Select potential regulators of myogenesis
affected by RUNX1, ZNF238, and miR-206.
Additional file 10: Figure S6. The miR-206 promoter in RD cells is
bound by MyoD and has acetylated histone H4. (A) ChIP for MyoD in RD
cells in differentiation media shows MyoD enrichment upstream of miR-
206, compared to a control locus at a non-expressed gene (hemoglobin
beta). (B) Site-specific ChIPs in RD cells for acetylated histone H4, at
hemoglobin beta (control), miR-206, and the myogenin promoter
(MYOG). ChIP results are represented as the mean ± SEM of at least three
independent experiments. Relative enrichment is calculated as the ratio
of the % of input amplified with antibody to the % of input amplified
with no antibody. *: P<0.05; **: P<0.01.
Additional file 11: Figure S7. MSC occupancy in the miR-206
promoter diminishes with MD~E differentiation. ChIP for MSC in the miR-
206 promoter in RD cells either transduced with empty virus (Control), or
differentiated through the expression of the forced MD~E protein dimer
(MD~E). Values are the means ± standard deviation of two independent
experiments. Corrected relative enrichment equals the relative
enrichment at miR-206/the relative enrichment at the control locus.
Relative enrichment is calculated as the ratio of the % of input amplified
with antibody to the % of input amplified with no antibody.
Additional file 12: Figure S8. In vitro assessment of MyoD and MSC
binding in the miR-206 promoter. Electrophoretic mobility shift assays
were performed using in vitro translated proteins as indicated and probes
that represent the DNA sequence under either the E-box occupied most
prominently by MyoD in RD cells as assessed by ChIP-seq results (MyoD-
binding E-box) or the E-box occupied most prominently by MSC (MSC-
binding E-box). Bound complexes were competed with cold competitor
probes prepared at the indicated excess.
Additional file 13: Figure S9. MSC inhibits the activation of the miR-
206 reporter by the forced MD~E dimer. Luciferase assay results in RD
cells using the miR-206 promoter reporter with constant amounts of
MyoD and E12 introduced individually or as the forced dimer, in the
presence of varying amounts of co-transfected MSC. - indicates no MSC
was added, 1x indicates that the MSC transfected was equal by mass to
the amount of MyoD or MD~E, and 0.1x indicates that the MSC
transfected was equal to 1/10th that amount. Results are indicated as the
means ± SEM from three independent experiments. Control indicates the
results from transfection with empty vector.
Additional file 14: Figure S10. Strong miR-206 activation is dependent
on multiple E-boxes. Luciferase assay results in RD cells with transient
transfection as indicated using the miR-206 promoter and a reporter in
which the E-box exhibiting the peak of MyoD occupancy in RD cells
(indicated by the red marker in Figure 5C) has been mutated and
eliminated as a site of bHLH binding. Results are indicated as the means
± SEM from three independent experiments. Control indicates the results
from transfection with empty vector. *: P<0.05.
Additional file 15: Figure S11. MD~E expression results in greater
myotube formation than MD~E2/5 expression. (A) Light microscopy
images of RD cells transduced with either control virus (Control) or virus
expressing either the MD~E or MD~E2/5 forced protein dimers and
allowed to differentiate for 24 h. Arrows indicate representative cells that
have appeared to form myotubes. (B) Western blot for MyoD and alpha-
tubulin, as a loading control, from cells treated as in (A). The size of the
bands detected with the MyoD antibody in MD~E and MD~E2/5 lanes
are as expected given the approximate calculated size of the forced
dimers.
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